Biomedicine is still "favored", these stocks meet the organization group research.

"
Pharmaceutical Network Pharmaceutical Stock Market" Wind data show that last week three trading days in the two cities a total of 34 listed companies to accept various types of institutional researchIn terms of industry distribution, biomedicine is still "favored"Specifically, Paulette, I Wu biological, Jincheng Pharmaceuticals and other biopharmaceutical industry stocks ushered in the organization of group research, Paulette welcomed the West Profit Fund, Wells Fargo Fund, Tianhong Fund, Yinhua Fund, Fuanda and dozens of other institutions of the joint researchIn the survey, the company said that the global awareness of medical security capabilities, inspired the construction of ICU and so onThe entire medical service system needs to be repositioned, and the equipment, function, compatibility and parameter platform will be upgradedIt is expected that the monitoring equipment will enter a golden period of rapid developmentdata show that Paulette is mainly engaged in the development, production, sales, services of medical devices, its main products for multi-parameter monitoring, mainly covering health monitoring and nephrology medical two business sectors: one is the health monitoring plate for medical monitoring equipment and ancillary products; The company's net profit attributable to shareholders of listed companies in 2019 was RMB64,712.8 millionI Wu biological ushered in the Huaxia Fund, Jianxin Pension, Xingquan Fund, Lianlian Assets, China Reinsurance (Group) and other 68 institutions 108 personnel of the investigationThe agency is concerned about whether the shorter summer vacation will have an impact on the company's third-quarter salesThe company said it could not be expected at this time, sales are still largely dependent on the number of hospital outpatients and patient visitsdata show that I Wu biological is a research and development, production and sales of biopharmaceutical products of high-tech enterprises, but also the current domestic production of standardized drug under the tongue of the companyAccording to the company's 2019 annual report, the company's net profit attributable to shareholders of listed companies in 2019 was RMB298 million, an increase of 28.09 percent over the same period last yearTianfeng Securities, Caitong Fund, Caitong Securities, Zhongyi Fund, Galaxy Securities, Huatai Assets, Guangfa Securities, Shanghai Zheninvestment and other 34 institutions to investigate Jincheng Pharmaceuticals, the content of the research is mainly related to the development of the company, including glutathione in the new field of application promotion, biological company adenosine sineline sales, terminal preparation plate can be expected in the future of new products, the company's new raw materials platform Jincheng Pharmaceuticals said in the survey, glutathione in new areas of application promotion includepig nutrition, aquatic nutrition, agriculture and other fields At present, the company mainly exports health care products level of adenosine methionine, the main market is North America, India, South America and Europe, the current company has 60 tons of production capacity, the company's 2019 sales of about 20 tons, the price of about 850,000 yuan per ton New products that can be expected in the end-end preparation ssector include: Cabea-Benbucosin Injection (Langkabehin) has now entered the on-site assessment phase and is expected to obtain approval in September or October this year, as appropriate In addition, proestrogene series approved three, the second half of last year has been Beijing, Gansu, Hubei, Jiangxi, Liaoning, Guangxi, Shandong and other places of the network successful, 2020 Proestrogen sales are expected to achieve rapid growth data show that Jincheng Pharmaceuticals landed in Shenzhen GEM in 2011, with from cephalosporine medicine in the middle, characteristics of raw materials, end-agent industry chain, the realization of the pharmaceutical chemical industry to biopharmaceuticals, and then to the end of the preparation of the two strategic transformation, the formation of three major industrial sectors, eight production bases, the north to Guangzhou industrial layout Group operating indicators continued to grow steadily, achieving operating income of 2,795 million yuan, 288 million yuan in taxes, total assets of 5.592 billion yuan, and net profit attributable to shareholders of 101 million yuan in the first quarter of 2020 .